Mon, June 27, 2022
Fri, June 24, 2022
Thu, June 23, 2022
Wed, June 22, 2022
Tue, June 21, 2022
Sun, June 19, 2022
Fri, June 17, 2022
Thu, June 16, 2022
Wed, June 15, 2022

Neena Bitritto-Garg Maintained (ACAD) at Strong Buy with Decreased Target to $19 on, Jun 22nd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-19-on-jun-22nd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Neena Bitritto-Garg of Citigroup, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Decreased Target from $32 to $19 on, Jun 22nd, 2022.

Neena has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 4 agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022


These are the ratings of the 5 analyists that currently disagree with Neena


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, June 21st, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022

Publication Contributing Sources